BMS-986253

DRUG8 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Netherlands Cancer Institute, Bristol-Myers Squibb, Mark Stein, Icahn School of Medicine at Mount Sinai

Conditions

Adenocarcinoma of the ProstateAntineoplastic AgentsAntineoplastic Agents, ImmunologicalCancerColon CarcinomaHematological MalignancyHepatocellular CarcinomaImmune Checkpoint Inhibitors

Phase 1

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

CompletedNCT03400332

Bristol-Myers SquibbCancer, Melanoma

Start: 2018-02-12End: 2025-12-04Updated: 2026-02-24

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Active, not recruitingNCT03689699

Mark SteinAdenocarcinoma of the Prostate, Prostate Cancer

Start: 2018-10-11End: 2026-01-31Updated: 2025-04-29

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

RecruitingNCT04572451

Yana NajjarAntineoplastic Agents, Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors +7

Start: 2021-11-29End: 2027-05-31Target: 50Updated: 2025-08-01

BMS-986253 in Myelodysplastic Syndromes

TerminatedNCT05148234

National Cancer Institute (NCI)Myelodysplastic Syndromes

Start: 2022-11-29End: 2023-07-03Updated: 2025-09-30

Phase 2

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Active, not recruitingNCT02451982

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPancreatic Cancer

Start: 2016-03-28End: 2026-05-31Target: 76Updated: 2025-12-03

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

RecruitingNCT03026140

The Netherlands Cancer InstituteColon Carcinoma

Start: 2017-03-29End: 2032-03-01Target: 353Updated: 2026-03-05

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Active, not recruitingNCT04123379

Icahn School of Medicine at Mount SinaiHepatocellular Carcinoma, Non-small Cell Lung Cancer

Start: 2020-03-05End: 2025-12-31Updated: 2025-01-17

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

TerminatedNCT04347226

Columbia UniversityHematological Malignancy, Sars-CoV2, Solid Tumor

Start: 2020-04-16End: 2021-03-01Updated: 2025-05-22

Related Papers

Supplementary Data File 2 from Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment

2025-11-03

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

2025-10-201 citations

Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.

Journal of Clinical Oncology2025-05-28

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

2024-09-1554 citations

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer

New England Journal of Medicine2024-06-05284 citations

The impact of <i>KRAS</i> mutations on the clinical outcome and immune response following immunotherapy for pancreatic cancer.

2024-06-012 citations

Abstract 1159: Machine learning integrating spatial omics uncovers humoral immunity patterns in intratumoral tertiary lymphoid structures in pancreatic cancer pathologic responders

Cancer Research2024-03-221 citations

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.

2023-06-2063 citations

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases

Journal of Clinical Investigation2023-05-1522 citations

Abstract 3241: Single-cell RNA and TCR sequencing of tumor infiltrating lymphocytes identifies changes in pancreatic ductal adenocarcinomas following neoadjuvant treatment with combined anti-PD-1 blocking and anti-CD137 agonist therapy

Cancer Research2023-04-04

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence

Cancer Research Communications2023-03-2214 citations

Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study

BMJ Open2023-03-012 citations

200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results

Immuno-Oncology Technology2022-12-013 citations

629 Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma

Regular and Young Investigator Award Abstracts2022-11-014 citations

Abstract CT119: A randomized, double-blind phase 2 evaluation of the anti-IL-8 monoclonal antibody BMS-986253 + nivolumab + ipilimumab vs nivolumab + ipilimumab in patients with advanced melanoma that progressed on/after anti-PD-(L)1 therapy

Cancer Research2022-06-151 citations

Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.

Journal of Clinical Oncology2022-06-0191 citations

A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).

Journal of Clinical Oncology2022-06-016 citations

Neoadjuvant and adjuvant antitumor vaccination alone or combination with PD1 blockade and CD137 agonism in patients with resectable pancreatic adenocarcinoma.

Journal of Clinical Oncology2022-01-199 citations

Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors.

Journal of Clinical Oncology2021-05-202 citations

394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

Regular and Young Investigator Award Abstracts2020-11-0115 citations

9 more papers not shown